Skip to main content

    Marta Rendon

    Triple-combination (TC) cream is a stable combination of fluocinolone acetonide 0.01%, hydroquinone 4%, and tretinoin 0.05%, and currently is the only US Food and Drug Administration-approved drug for the topical treatment of melasma.... more
    Triple-combination (TC) cream is a stable combination of fluocinolone acetonide 0.01%, hydroquinone 4%, and tretinoin 0.05%, and currently is the only US Food and Drug Administration-approved drug for the topical treatment of melasma. Furthermore, it is the only US Food and Drug Administration-approved product containing hydroquinone. Anecdotal evidence suggests that improvements in melasma can be achieved with a multifactor approach involving TC cream with a variety of procedures. A pilot study was designed to evaluate the efficacy and safety of sequential treatment with TC cream and a series of glycolic acid (GA) peels in participants with moderate to severe melasma. Participants were treated with TC cream for 2 weeks before the alternating sequential treatment cycles with TC cream and GA peels began. A total of six 2-week cycles of TC cream and 5 GA peels were used. Efficacy and safety evaluations were conducted at weeks 6 and 12. Investigator global assessment (IGA) ratings indi...
    ... Triple Combination Cream and Glycolic Acid Peels for the Treatment of Moderate to Severe Melasma. Rendon, Marta MD1; Colon, Luz E. MS, CCRC, CCRA2; Johnson, Lori PhD2. ... Taylor, SC, Torok, H., Jones, T., Lowe, N., Rich, P., Tschen,... more
    ... Triple Combination Cream and Glycolic Acid Peels for the Treatment of Moderate to Severe Melasma. Rendon, Marta MD1; Colon, Luz E. MS, CCRC, CCRA2; Johnson, Lori PhD2. ... Taylor, SC, Torok, H., Jones, T., Lowe, N., Rich, P., Tschen, E., et al. (2003). ...
    Treatment of melasma involves the use of a range of topical depigmenting agents and physical therapies. Varying degrees of success have been achieved with these therapies. The Pigmentary Disorders Academy (PDA) undertook to evaluate the... more
    Treatment of melasma involves the use of a range of topical depigmenting agents and physical therapies. Varying degrees of success have been achieved with these therapies. The Pigmentary Disorders Academy (PDA) undertook to evaluate the clinical efficacy of the different treatments of melasma in order to generate a consensus statement on its management. Clinical papers published during the past 20 years were identified through MEDLINE searches and methodology and outcome assessed according to guidelines adapted from the US Preventive Services Task Force (USPSTF). The consensus of the group was that first-line therapy for melasma should consist of effective topical therapies, mainly fixed triple combinations. Where patients have either sensitivity to the ingredients or a triple combination therapy is unavailable, other compounds with dual ingredients (hydroquinone plus glycolic acid) or single agents (4% hydroquinone, 0.1% retinoic acid, or 20% azelaic acid) may be considered as an alternative. In patients who failed to respond to therapy, options for second-line therapy include peels either alone or in combination with topical therapy. Some patients will require therapy to maintain remission status and a combination of topical therapies should be considered. Lasers should rarely be used in the treatment of melasma and, if applied, skin type should be taken into account.
    The efficacy of sertaconazole in the treatment of tinea pedis in patients with co-morbid onychomycosis was evaluated in a double-blind, vehicle-controlled six-week clinical trial in 23 patients, ages 43-83 years. Subjects applied either... more
    The efficacy of sertaconazole in the treatment of tinea pedis in patients with co-morbid onychomycosis was evaluated in a double-blind, vehicle-controlled six-week clinical trial in 23 patients, ages 43-83 years. Subjects applied either sertaconazole 2% or placebo cream twice daily to the affected areas for 4 weeks. Subjects were required to have clinic visits at baseline and weeks 2, 4 and 6. A mycobiological evaluation including KOH and DTM preparation, PAS of toenail(s) was performed at baseline. Fungal cultures were completed at visit 6. Only local side effects were recorded and reported by participants. Photographic evidence was also collected at baseline and throughout the study to document the progress of treatment. To date, 11 patients were randomized to receive sertaconazole and 12 to placebo. A total of 23 patients were enrolled. An assessment of the mycological cure rate and negative fungal cultures at week 6 was obtained in all subjects. Conclusion: Sertaconazole, an imi...
    Research Interests: